TY - JOUR
T1 - Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome
AU - Salles, Évila Lopes
AU - Khodadadi, Hesam
AU - Jarrahi, Abbas
AU - Ahluwalia, Meenakshi
AU - Paffaro, Valdemar Antonio
AU - Costigliola, Vincenzo
AU - Yu, Jack C.
AU - Hess, David C.
AU - Dhandapani, Krishnan M.
AU - Baban, Babak
N1 - Funding Information:
This work was sponsored by institutional seed money of Dental College of Georgia (DCG) and Medical College of Georgia (MCG) jointly, as well as by National Institute of Health award (R01NS110378) . The funding organizations had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Publisher Copyright:
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
PY - 2020/11
Y1 - 2020/11
N2 - Considering lack of target-specific antiviral treatment and vaccination for COVID-19, it is absolutely exigent to have an effective therapeutic modality to reduce hospitalization and mortality rate as well as to improve COVID-19-infected patient outcomes. In a follow-up study to our recent findings indicating the potential of Cannabidiol (CBD) in the treatment of acute respiratory distress syndrome (ARDS), here we show for the first time that CBD may ameliorate the symptoms of ARDS through up-regulation of apelin, a peptide with significant role in the central and peripheral regulation of immunity, CNS, metabolic and cardiovascular system. By administering intranasal Poly (I:C), a synthetic viral dsRNA, while we were able to mimic the symptoms of ARDS in a murine model, interestingly, there was a significant decrease in the expression of apelin in both blood and lung tissues. CBD treatment was able to reverse the symptoms of ARDS towards a normal level. Importantly, CBD treatment increased the apelin expression significantly, suggesting a potential crosstalk between apelinergic system and CBD may be the therapeutic target in the treatment of inflammatory diseases such as COVID-19 and many other pathologic conditions.
AB - Considering lack of target-specific antiviral treatment and vaccination for COVID-19, it is absolutely exigent to have an effective therapeutic modality to reduce hospitalization and mortality rate as well as to improve COVID-19-infected patient outcomes. In a follow-up study to our recent findings indicating the potential of Cannabidiol (CBD) in the treatment of acute respiratory distress syndrome (ARDS), here we show for the first time that CBD may ameliorate the symptoms of ARDS through up-regulation of apelin, a peptide with significant role in the central and peripheral regulation of immunity, CNS, metabolic and cardiovascular system. By administering intranasal Poly (I:C), a synthetic viral dsRNA, while we were able to mimic the symptoms of ARDS in a murine model, interestingly, there was a significant decrease in the expression of apelin in both blood and lung tissues. CBD treatment was able to reverse the symptoms of ARDS towards a normal level. Importantly, CBD treatment increased the apelin expression significantly, suggesting a potential crosstalk between apelinergic system and CBD may be the therapeutic target in the treatment of inflammatory diseases such as COVID-19 and many other pathologic conditions.
KW - ARDS
KW - CBD
KW - COVID-19
KW - apelin
KW - cannabidiol
KW - inflammation
UR - http://www.scopus.com/inward/record.url?scp=85092488899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092488899&partnerID=8YFLogxK
U2 - 10.1111/jcmm.15883
DO - 10.1111/jcmm.15883
M3 - Article
C2 - 33058425
AN - SCOPUS:85092488899
SN - 1582-1838
VL - 24
SP - 12869
EP - 12872
JO - Journal of Cellular and Molecular Medicine
JF - Journal of Cellular and Molecular Medicine
IS - 21
ER -